Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Middle East respiratory syndrome coronavirus vaccine - Vaccitech

Drug Profile

Middle East respiratory syndrome coronavirus vaccine - Vaccitech

Alternative Names: ChAdOx1 MERS vaccine; MERS vaccine - Vaccitech; MERS-CoV vaccine – Vaccitech; VTP-500

Latest Information Update: 27 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Investment Partners; Vaccitech
  • Developer University of Oxford; Vaccitech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 23 Dec 2019 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in Saudi Arabia (IM)
  • 27 Sep 2018 Janssen Vaccines & Prevention B.V., the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford enter into a collaboration to develop and manufacture ChAdOx1 vaccine against Middle East Respiratory Syndrome Coronavirus
  • 27 Sep 2018 Oxford University in-licenses certain rights to Middle East respiratory syndrome coronavirus vaccine from Vaccitech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top